Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery
Launched by ENIKAM D.O.O. · May 15, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a mouthwash called OROXID® to see if it can help people heal better after having their wisdom teeth removed. The researchers believe that OROXID® might reduce pain and complications after surgery and promote faster healing by cleaning the mouth and reducing bacteria. This mouthwash works by releasing oxygen bubbles that help remove debris and keeps the area moist, which is important for healing.
To participate in the trial, you need to be at least 18 years old and in good health. You should be scheduled for oral surgery, like wisdom tooth extraction, and be willing to follow post-surgery care instructions. However, if you've had certain dental treatments recently, have specific oral health issues, or are pregnant or breastfeeding, you may not be eligible to join. Participants will use OROXID® as directed and monitor their recovery, helping researchers understand its effectiveness and safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Systemically healthy individuals aged 18 years or older.
- • 2. Indicated for surgical removal of an erupted or unerupted tooth and/or apicoectomy.
- • 3. Ability and willingness to comply with post-operative oral hygiene instructions.
- • 4. Signed informed consent form prior to participation in the study.
- Exclusion Criteria:
- • 1. Receipt of periodontal treatment within the past 3 months.
- • 2. Use of mouthwashes or oral gels in the past month.
- • 3. Presence of active gingivitis around the tooth scheduled for extraction.
- • 4. Known allergy to any ingredients of the investigational products.
- • 5. Presence of inflammatory conditions in the oral cavity, such as lichen planus, bullous lesions, or active gingivitis.
- • 6. Immunocompromised individuals.
- • 7. Known allergy to penicillin or diclofenac.
- • 8. Pregnant or breastfeeding women.
- • 9. Smokers who consume more than 15 cigarettes per day.
About Enikam D.O.O.
Enikam d.o.o. is a forward-thinking clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, Enikam partners with healthcare professionals and research institutions to conduct rigorous clinical trials that adhere to the highest ethical and regulatory standards. The company is committed to enhancing patient outcomes through evidence-based practices and cutting-edge methodologies, fostering collaboration across diverse therapeutic areas. Enikam’s expertise and dedication to scientific excellence position it as a pivotal player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Muljava, Ivančna Gorica, Slovenia
Muljava, , Slovenia
Patients applied
Trial Officials
Tadej Dovšak, PhD
Principal Investigator
Krizaj d.o.o.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported